Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 7
Submit an article Journal homepage
367
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy

Adisak TantiworawitLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
Maryse M. PowerLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
Michael J. BarnettLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
Donna E. HoggeLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
Stephen H. NantelLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
Thomas J. NevillLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
John D. ShepherdLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
Kevin W. SongLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
Heather J. SutherlandLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
Cynthia L. TozeLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
Yasser R. Abou-MouradLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
Sujaatha NarayananLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
,
Raewyn C. BroadyLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
&
Donna L. ForrestLeukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada and the British Columbia Cancer Agency, Vancouver, British Columbia, CanadaCorrespondence[email protected]
 show all
Pages 1321-1326 | Received 19 Oct 2011, Accepted 18 Dec 2011, Published online: 05 Mar 2012

References

  • Hochhaus A, O’Brien SG, Guilhot F, . Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054–1061.
  • Jabbour E, Kantarjian H, O’Brien S, . Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 2006;107:480–482.
  • Alimena G, Breccia M, Latagliata R, . Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer 2006;107:1008–1013.
  • Kantarjian H, O’Brien S, Cortes J, . Sudden onset of the blastic phase of chronic myelogenous leukemia:patterns and implications. Cancer 2003;98:81–85.
  • Kim A, Goldstein S, Luger S, . Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia. Am J Clin Pathol 2008;129:639–648.
  • Ali R, Ozkalemkas F, Ozkocaman V, . Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era. Int J Clin Oncol 2009;14:545–550.
  • Avery S, Nadal E, Marin D, . Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. Leuk Res 2004;28(Suppl. 1):S75–S77.
  • Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia. Semin Hematol 2003;40:62–68.
  • Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999;107: 587–599.
  • Baccarani M, Saglio G, Goldman J, . Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–1820.
  • Baccarani M, Cortes J, Pane F, . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
  • Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons; 1998.
  • Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
  • Hughes T, Hochhaus A, Branford S, . Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Rando–mized Study of Interferon and ST1571 (IRIS). Blood 2010;116:3758–3765.
  • Kantarjian H, O’Brien S, Shan J, . Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer 2008;112:837–845.
  • Jiang X, Forrest D, Nicolini F, . Properties of CD34 + CML/stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood 2010;116:2112–2121.
  • Saglio G, Kim DW, Issaragrisil S, . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251–2259.
  • Kantarjian H, Shah N, Hochhaus A, . Dasatinib versus imantinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
  • Wadhwa J, Szydlo R, Apperley J, . Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002;99:2304–2309.
  • Kantarjian H, Cortes J, O’Brien S, . Imatinib mesylate (ST1571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547–3553.
  • Wright M, Shepherd J, Barnett M, . Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:639–646.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.